Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
- Market Cap ₹ 4,259 Cr.
- Current Price ₹ 381
- High / Low ₹ 425 / 291
- Stock P/E 34.6
- Book Value ₹ 51.9
- Dividend Yield 1.34 %
- ROCE 27.6 %
- ROE 22.3 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 28.4% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 31.1%
Cons
- Stock is trading at 7.34 times its book value
- Promoter holding has decreased over last quarter: -0.47%
- The company has delivered a poor sales growth of 10.5% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
141 | 135 | 125 | 139 | 173 | 212 | 222 | 247 | 283 | 273 | 312 | 365 | |
101 | 107 | 91 | 103 | 124 | 162 | 169 | 170 | 183 | 200 | 236 | 260 | |
Operating Profit | 39 | 28 | 34 | 36 | 48 | 50 | 53 | 77 | 101 | 73 | 76 | 105 |
OPM % | 28% | 21% | 27% | 26% | 28% | 24% | 24% | 31% | 36% | 27% | 24% | 29% |
2 | 1 | 1 | 1 | 6 | 5 | 6 | 9 | 7 | 9 | 9 | 40 | |
Interest | 4 | 8 | 5 | 4 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0 |
Depreciation | 7 | 9 | 8 | 7 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 11 |
Profit before tax | 31 | 12 | 23 | 25 | 44 | 44 | 47 | 76 | 98 | 72 | 74 | 134 |
Tax % | 30% | 16% | 14% | 18% | 21% | 18% | 25% | 24% | 28% | 24% | 25% | 19% |
21 | 10 | 20 | 21 | 35 | 36 | 35 | 58 | 71 | 55 | 56 | 108 | |
EPS in Rs | 1.97 | 0.91 | 1.81 | 1.92 | 3.10 | 3.22 | 3.16 | 5.19 | 6.36 | 4.88 | 4.97 | 9.67 |
Dividend Payout % | 15% | 11% | 6% | 10% | 13% | 16% | 19% | 12% | 14% | 21% | 20% | 53% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 10% |
3 Years: | 9% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 29% |
5 Years: | 28% |
3 Years: | 20% |
TTM: | 120% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | -2% |
1 Year: | 23% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 16% |
3 Years: | 15% |
Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Reserves | 107 | 116 | 134 | 152 | 233 | 267 | 297 | 348 | 413 | 458 | 503 | 558 |
61 | 59 | 38 | 49 | 38 | 45 | 18 | 10 | 1 | 2 | 2 | 2 | |
43 | 31 | 28 | 37 | 25 | 39 | 38 | 42 | 53 | 48 | 48 | 51 | |
Total Liabilities | 233 | 228 | 223 | 261 | 318 | 373 | 376 | 423 | 490 | 530 | 576 | 633 |
114 | 110 | 106 | 101 | 98 | 98 | 97 | 127 | 132 | 132 | 143 | 142 | |
CWIP | 0 | 2 | 5 | 7 | 8 | 10 | 7 | 10 | 7 | 9 | 11 | 22 |
Investments | 28 | 28 | 27 | 53 | 103 | 120 | 120 | 121 | 184 | 189 | 201 | 256 |
91 | 88 | 84 | 99 | 108 | 145 | 151 | 165 | 166 | 200 | 220 | 213 | |
Total Assets | 233 | 228 | 223 | 261 | 318 | 373 | 376 | 423 | 490 | 530 | 576 | 633 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
18 | 18 | 33 | 22 | 21 | 23 | 35 | 46 | 84 | 37 | 50 | 56 | |
-28 | -7 | -7 | -27 | -55 | -22 | -2 | -25 | -70 | -14 | -42 | -7 | |
8 | -11 | -27 | 4 | 34 | -1 | -33 | -19 | -15 | -11 | -12 | -57 | |
Net Cash Flow | -2 | -0 | -1 | -0 | -0 | -0 | 0 | 2 | -1 | 12 | -4 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 77 | 71 | 60 | 65 | 66 | 63 | 77 | 70 | 66 | 78 | 75 |
Inventory Days | 304 | 363 | 389 | 393 | 300 | 234 | 249 | 245 | 240 | 295 | 228 | 268 |
Days Payable | 151 | 90 | 74 | 75 | 50 | 90 | 66 | 56 | 85 | 75 | 54 | 60 |
Cash Conversion Cycle | 240 | 350 | 386 | 378 | 316 | 210 | 246 | 265 | 226 | 286 | 252 | 283 |
Working Capital Days | 120 | 112 | 126 | 142 | 153 | 114 | 120 | 138 | 110 | 142 | 132 | 139 |
ROCE % | 20% | 10% | 14% | 14% | 18% | 15% | 15% | 21% | 24% | 15% | 15% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Jul - Copy of newspaper publication of ''Notice of Equity Shareholders of the Company regarding transfer of Shares to the Investor Education & Protection Fund (IEPF) and …
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Jul
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Jul - Revised Newspaper Publication - Navshakti , issue date July 03, 2024
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jul - Newspaper Publication: NavShakti and Free Press Journal July 02, 2024
- Business Responsibility and Sustainability Reporting (BRSR) 1 Jul
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2006
from bse
Concalls
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Sep 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Nov 2017TranscriptPPT
-
Sep 2017Transcript PPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
May 2017TranscriptNotesPPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Nov 2016TranscriptPPT
Market Position
The Co. is the 1st Indian enzyme company with 2nd highest market share in India. It is the 2nd listed integrated enzyme player globally. [1]